Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the therapeutic potential of potassium channel openers for various conditions related to metabolic distress but does not report new clinical results; it emphasizes the need for further research.

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This study found that several newly synthesized dihydrobenzopyran compounds inhibited insulin secretion and had vasorelaxant activity, with some more potent than reference KATP channel activators, though compound 21 functioned as a Ca2+ entry blocker.

This review discusses the challenges in developing combination therapies for urological conditions and notes that regulatory requirements and financial disincentives hinder progress, without presenting new clinical findings.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This review discusses the drug treatment of benign prostatic syndrome, highlighting the efficacy of combination therapies over monotherapies in patients at high risk for disease progression, but notes increased side effects and costs.

This study found that 1,25 dihydroxyvitamin D3 significantly increased the expression and activity of vasculoprotective natriuretic peptide receptor-A in cultured inner medullary collecting duct cells, suggesting a potential mechanistic role in cardiovascular and renal benefits.

This case report highlights a 37-year-old male who developed coronary vasospasm, resembling Prinzmetal angina, shortly after starting oral minoxidil for hair loss, emphasizing the need to consider drug-induced vasospasm in chest pain assessments even when coronary artery disease is absent.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.

This review discusses the role of norepinephrine release and protein kinase C activation in the development of benign prostatic hypertrophy, suggesting potential targets for new therapies, but it reports no new clinical results.

This review discusses the potential role of autonomic dysfunction and sympathetic overactivity in hypertension development and reports no new results; renal denervation therapies have gained popularity for resistant cases.

This study suggested that minoxidil's neuroprotective effect in mice was independent of its blood pressure-lowering action, unlike the effects observed with losartan and doxazosin.

This study found that young men with post-finasteride syndrome may experience erectile dysfunction due to potential histologic changes in penile tissue, despite having normal penile Doppler hemodynamics.

In this study, researchers developed hyaluronic acid derivatives functionalized with nitric oxide photodonors for light-activated skin treatments, finding that the compounds released NO under blue light and enhanced keratinocyte proliferation and migration, suggesting potential for therapeutic use.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This article reviews the mechanisms and uses of minoxidil for hypertension and androgenetic alopecia, without presenting new clinical findings.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This study found that minoxidil effectively reduced blood pressure in patients with severe hypertension and renal failure resistant to conventional drugs, though side effects like hirsutism and edema were common.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.

This study found that multiple ion channel modulators, used here at clinical concentrations, increased intracellular calcium release in prostate and breast cancer cell lines.

This review reports that combination therapy with 5α-reductase inhibitors and α1-receptor blockers does not appear to benefit patients with benign prostatic hyperplasia and prostate volumes up to 40–45 ml, but may be more effective for larger prostate volumes.

This study found that terazosin, finasteride, or their combination were effective in treating symptoms of benign prostatic hyperplasia.

Human platelets change minoxidil to minoxidil sulfate, helping blood vessels widen.

This article suggests using nicotinamide and minoxidil as potassium channel activators to target solid tumors, but reports no new clinical results and calls for further research.

This study found that topical application of N,N-dimethylglycine sodium salt increased dermal blood flow and velocity in human subjects, likely through its effects on endothelial cells and NO-dependent vasodilation.

This study found that minoxidil significantly reduced blood pressure in patients with intractable hypertension and was generally well-tolerated, although fluid retention and hirsutism posed some challenges.

This case report describes how nitroglycerin (sublingual) was used to prevent further scalp necrosis during hair restoration surgery, particularly in a patient experiencing early necrosis linked to local anesthetics with epinephrine.